In vitro and in vivo effects of a nutrient mixture on breast cancer progression

Roomi,M. W.; Kalinovsky,T.; Roomi,N. M.; Cha,J.; Rath,M.; Niedzwiecki,A.

doi:10.3892/ijo.2014.2379

In vitro and in vivo effects of a nutrient mixture on breast cancer progression

Authors:
- M. W. Roomi
- T. Kalinovsky
- N. M. Roomi
- J. Cha
- M. Rath
- A. Niedzwiecki
View Affiliations

Affiliations: Dr. Rath Research Institute, Santa Clara, CA 95050, USA
Published online on: April 10, 2014 https://doi.org/10.3892/ijo.2014.2379
Pages: 1933-1944

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long-term survival of patients with breast cancer remains poor, due to metastasis and recurrence. We investigated the effects of a novel nutrient mixture (NM) containing ascorbic acid, lysine, proline and green tea extract in vitro and in vivo on 4T1 murine breast cancer, a representative model for metastatic breast cancer. After one week of isolation, 5-6-week-old female Balb/C mice were inoculated with 5x105 4T1 cells into the mammary pad and randomly divided into two groups; the control group was fed a regular diet and the NM group a regular diet supplemented with 0.5% NM. After four weeks, the mice were sacrificed and their tumors, lungs, livers, kidneys, hearts and spleens were excised and processed for histology. Dimensions (length and width) of tumors were measured using a digital caliper, and the tumor burden was calculated using the following formula: 0.5 x length x width. We also tested the effect of NM in vitro on 4T1 cells, measuring cell proliferation by MTT assay, MMP secretion by zymography, invasion through Matrigel, migration by scratch test and morphology by H&E staining. NM inhibited tumor weight and burden of 4T1 tumors by 50% (p=0.02) and 53.4% (p≤0.0001), respectively. Lung metastasis was profoundly inhibited by NM supplementation: mean number of colonies was reduced by 87% (p<0.0001) and mean weight of lungs by 60% (p=0.0001) compared to control mice. Metastasis to liver, spleen, kidney and heart was significantly reduced with NM supplementation. In vitro, NM exhibited 50% toxicity over the control at 250 and 500 µg/ml concentrations. Zymography demonstrated MMP-2 and MMP-9 secretion which was inhibited by NM in a dose-dependent manner, with virtual total inhibition of both at 1,000 µg/ml. Migration by scratch test and invasion through Matrigel were inhibited in a dose-dependent manner with total block of invasion at 250 and of migration at 1,000 µg/ml. These results suggest that NM has therapeutic potential in the treatment of breast cancer.

View Figures

View References

1.	American Cancer Society: Breast cancer: what are the key statistics about breast cancer? http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics). Accessed 10/9/13. Last Medical Review: 09/11/2013. Last Revised: 10/01/2013.
2.	Ali SM, Harvey HA and Lipton A: Metastatic breast cancer: overview of treatment. Clin Orthop. 414(Suppl): 132–137. 2003. View Article : Google Scholar
3.	Fidler IJ: Molecular biology of cancer: invasion and metastasis. Cancer: Principles and Practice of Oncology. 5th edition. De Vita VT, Hellman S and Rosenberg SA: Lippincott-Raven; Philadelphia, PA: pp. 135–152. 1997
4.	Rath M and Pauling L: Plasmin-induced proteolysis and the role of apoprotein(a), lysine and synthetic analogs. Orthomolecular Med. 7:17–23. 1992.
5.	Niedzwiecki A, Roomi MW, Kalinovsky T and Rath M: Micronutrient synergy - a new tool in effective control of metastasis and other key mechanisms of cancer. Cancer Metastasis Rev. 29:529–543. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Bibby MC: Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer. 40:852–857. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Eccles SA, Box G, Court W, Sandle J and Dean CJ: Preclinical models for the evaluation of targeted therapies of metastatic disease. Cell Biophys. 24–25:279–291. 1994.
8.	Hoffman RM: Orthotopic metastatic mouse models for anti-cancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs. 17:343–359. 1999. View Article : Google Scholar : PubMed/NCBI
9.	Vernon E, Bakewell SJ and Chodash LA: Deciphering the molecular basis of breast cancer metastasis with mouse models. Rev Endocr Metab Disord. 8:199–213. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Tao K, Fang M, Aloy J and Sahagian GG: Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer. 8:2282008. View Article : Google Scholar : PubMed/NCBI
11.	Aslakson CJ and Miller FR: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52:1399–1405. 1992.PubMed/NCBI
12.	Bonfil RD, Bustuabad OD, Ruggiero RA, Meiss RP and Pasqualini CD: Tumor necrosis can facilitate the appearance of metastases. Clin Exp Metastasis. 6:121–129. 1988. View Article : Google Scholar : PubMed/NCBI
13.	Bonfil RD, Medina PA, Gómez DE, Farías E, Lazarowski A, Lucero Gritti MF, Meiss RP and Bustuabad OD: Expression of gelatinase/type IV collagenase in tumor necrosis correlates with cell detachment and tumor invasion. Clin Exp Metastasis. 10:211–220. 1992. View Article : Google Scholar : PubMed/NCBI
14.	Cha J, Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A and Rath M: Ascorbate supplementation inhibits growth and metastasis of B16FO melanoma and 4T1 breast cancer cells in vitamin C deficient mice. Int J Oncol. 42:55–64. 2013.PubMed/NCBI
15.	Bachmeier BE, Nerlich AG, Lichtinghagen R and Sommerhoff CP: Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity. Anticancer Res. 6A:3821–3828. 2001.PubMed/NCBI
16.	Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ and Kosma VM: Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER-2, and prognosis. Clin Cancer Res. 10:7621–7628. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Connolly EM, Harmey JH, O'Grady T, Foley D, Roche-Nagle G, Kay E and Bouchier-Hayes DJ: Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br J Cancer. 87:231–237. 2002. View Article : Google Scholar : PubMed/NCBI
18.	Denardo DG, Johansson M and Coussans LM: Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 27:11–18. 2008. View Article : Google Scholar : PubMed/NCBI
19.	van Kempen LC, de Visser KE and Coussens LM: Inflammation, proteases and cancer. Eur J Cancer. 42:728–734. 2006.PubMed/NCBI
20.	Roomi MW, Kalinovsky T, Roomi NW, Rath M and Niedzwiecki A: Inhibition of growth and expression of inflammation mediators in human leukemic cell line. Exp Oncol. 35:180–186. 2013.PubMed/NCBI
21.	Roomi MW, Kalinovsky T, Niedzwiecki A and Rath M: Pleiotropic effects of a micronutrient mixture on critical parameters of bladder cancer. Bladder Cancer Etymology, Diagnosis and Treatments. Nilsson WE: Nova Science Publishers, Inc.; New York: 2009
22.	Sun Z, Chen YH, Wang P, Zhang J, Gurewich V, Zhang P and Liu JN: The blockage of high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochem Biophys Acta. 1596:182–192. 2002.PubMed/NCBI
23.	Valcic S, Timmermann BN, Alberts DS, Wachter GA, Krutzsch M, Wymer J and Guillen JM: Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs. 7:461–468. 1996. View Article : Google Scholar : PubMed/NCBI
24.	Mukhtar H and Ahmed N: Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr. 71:S1698–S1702. 2000.PubMed/NCBI
25.	Yang GY, Liao J, Kim K, Yurtow EJ and Yang CS: Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis. 19:611–616. 1998. View Article : Google Scholar : PubMed/NCBI
26.	Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H and Shimikawa R: Effect of (−) epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett. 65:51–54. 1992.
27.	Hara Y: Green tea: Health Benefits and Applications. Marcel Dekker; New York, Basel: 2001, View Article : Google Scholar
28.	Kawakami S, Kageyama Y, Fujii Y, Kihara K and Oshima H: Inhibitory effects of N-acetyl cysteine on invasion and MMP 9 production of T24 human bladder cancer cells. Anticancer Res. 21:213–219. 2001.PubMed/NCBI
29.	Morini M, Cai T, Aluigi MG, Noonan DM, Masiello L, De Floro S, D’Agostinin F, Albini A and Fassima G: The role of the thiol N-acetyl cysteine in the prevention of tumor invasion and angiogenesis. Int J Biol Markers. 14:268–271. 1999.PubMed/NCBI
30.	Yoon SO, Kim MM and Chung AS: Inhibitory effects of selenite on invasion of HT 1080 tumor cells. J Biol Chem. 276:20085–20092. 2001. View Article : Google Scholar : PubMed/NCBI
31.	Naidu KA, Karl RC and Coppola D: Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: association with decreased expression of insulin-like growth factor 1 receptor. Dig Dis Sci. 48:230–237. 2003. View Article : Google Scholar : PubMed/NCBI
32.	Anthony HM and Schorah CJ: Severe hypovitaminosis C in lung-cancer patients: the utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer. 46:354–367. 1982. View Article : Google Scholar : PubMed/NCBI
33.	Maramag C, Menon M, Balaji KC, Reddy PG and Laxmanan S: Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability and DNA synthesis. Prostate. 32:188–195. 1997. View Article : Google Scholar : PubMed/NCBI
34.	Koh WS, Lee SJ, Lee H, Park C, Park MH, Kim WS, Yoon SS, Park K, Hong SI, Chung MH and Park CH: Differential effects and transport kinetics of ascorbate derivatives in leukemic cell lines. Anticancer Res. 8:2487–2493. 1998.PubMed/NCBI
35.	Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA. 102:13604–13609. 2005. View Article : Google Scholar : PubMed/NCBI
36.	Nunez C, Ortiz de Apodaca Y and Ruiz A: Ascorbic acid in the plasma and blood cells of women with breast cancer. The effect of consumption of food with an elevated content of this vitamin. Nutr Hosp. 10:368–372. 1995.PubMed/NCBI
37.	Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett. 103:183–189. 1996. View Article : Google Scholar : PubMed/NCBI
38.	Cooke JP and Dzau VJ: Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med. 48:489–509. 1997. View Article : Google Scholar : PubMed/NCBI